Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.

Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin (vitamin B2) can saturate presystemic metabolism, leading to increased bioavailability. This means that a small change in the dose of riboflavin can result in a large variation in its plasma concentration.

Nonlinear distribution occurs due to the saturation of binding sites on plasma proteins or tissue binding sites. Phenylbutazone (Butazolidine), a nonsteroidal anti-inflammatory drug, provides an example of this phenomenon. Phenylbutazone can saturate its plasma protein binding sites at high concentrations, increasing the drug's unbound fraction. This unbound fraction is pharmacologically active and can lead to enhanced therapeutic effects or potential toxicity.

Nonlinearity in metabolism can arise from capacity-limited metabolism due to enzyme saturation or induction. Carbamazepine (Tegretol), an anticonvulsant and mood-stabilizing drug, is a prime example. Repetitive administration of carbamazepine can induce its own metabolism, leading to a decrease in peak plasma concentration. This phenomenon, known as autoinduction, can affect drug efficacy and requires dose adjustments.

Nonlinear renal excretion can occur due to saturation of the tubular carrier system. When transporters involved in the reabsorption of glucose and water-soluble vitamins become saturated, they can increase renal clearance of these substances.

Pathological changes can also cause nonlinear kinetics. For instance, aminoglycosides, a class of antibiotics, can induce renal nephrotoxicity, which alters renal drug excretion. This can affect the clearance of drugs primarily excreted by the kidneys, leading to their accumulation and potential toxicity.

From Chapter 8:

article

Now Playing

8.2 : Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinear Pharmacokinetics

41 Views

article

8.1 : Nonlinear Pharmacokinetics: Overview

Nonlinear Pharmacokinetics

114 Views

article

8.3 : Nonlinear Pharmacokinetics: Michaelis-Menten Equation

Nonlinear Pharmacokinetics

60 Views

article

8.4 : Determination of Michaelis Constant and Maximum Elimination Rate

Nonlinear Pharmacokinetics

21 Views

article

8.5 : Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection

Nonlinear Pharmacokinetics

12 Views

article

8.6 : Drug Distribution as One-Compartment Model and Elimination by Nonlinear Pharmacokinetics: Overview

Nonlinear Pharmacokinetics

15 Views

article

8.7 : Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model

Nonlinear Pharmacokinetics

13 Views

article

8.8 : Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics

18 Views

article

8.9 : Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Nonlinear Pharmacokinetics

27 Views

article

8.10 : Chronopharmacokinetics: Time-Dependent Pharmacokinetics

Nonlinear Pharmacokinetics

35 Views

article

8.11 : Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

Nonlinear Pharmacokinetics

49 Views

article

8.12 : Nonlinear Pharmacokinetics: Role of Transporters

Nonlinear Pharmacokinetics

13 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved